Skip to content
U.S. Transhumanist Party – Official Website
  • Home
  • Posts
  • Values
  • Platform
  • Leadership
  • Advisors
  • Candidates
  • Highlights
  • FAQ
  • States & Allies
  • Free Membership
  • Facebook
  • Twitter
  • Search Icon

U.S. Transhumanist Party – Official Website

U.S. Transhumanist Party – PUTTING SCIENCE, HEALTH, & TECHNOLOGY AT THE FOREFRONT OF AMERICAN POLITICS

Stem-Cell Clinical Trials Show Remarkable Results Against Age-Related Frailty – Article by Steve Hill

Stem-Cell Clinical Trials Show Remarkable Results Against Age-Related Frailty – Article by Steve Hill

October 30, 2017 Steve Hill Comments 1 comment

Steve Hill


Editor’s Note: In this article, Mr. Steve Hill discusses two very promising human clinical trials using stem cell therapy for age-related frailty. This article was originally published by the Life Extension Advocacy Foundation (LEAF) .

~ Kenneth Alum, Director of Publication, U.S. Transhumanist Party, October 29, 2017

The first results of two human clinical trials using stem cell therapy for age-related frailty have been published, and the results are very impressive indeed. The studies show that the approach used is effective in tackling multiple key age-related factors.

Aging research has made significant progress in the last few years, with senescent-cell-clearing therapies entering human trials this year, DNA repair in human trials, and a number of other exciting therapies nearing human testing. We are reaching the point where therapies that target aging processes are no longer a matter of speculation; they are now an undeniable matter of fact.

What are mesenchymal stem cells?

Mesenchymal stem cells (MSCs) are one of the most commonly used types of stem cells in therapy. MSCs are adult stem cells that can become other types of cells, depending on stimulus; this ability to become a variety of other cell types is known as multipotency.Ā [1]

The cells into which MSCs can transform (differentiate) include osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells), and adipocytes (fat cells). MSCs are of great interest to aging researchers and are arguably one of the most well studied and understood types of stem cells.Ā [2]

MSCs are currently in various trials to treat conditions such as cancer, heart disease, and arthritis.Ā [3] The potential of MSCs for treating neurodegenerative diseases, such as Alzheimer’s, are also being explored in preclinical testing.Ā [4-5]

A therapy for age-related frailty

The focus of the MSC therapy in the case of these two clinical trials is to reduce the effects of age-related frailty on senior citizens. This also marks an important step for rejuvenation biotechnology, as this is the first stem-cell treatment that is close to final FDA approval for specifically targeting age-related frailty. Should this be approved, then it opens the door for other similar approaches and the potential treatment of many age-related diseases.

The therapy itself uses MSCs taken from adult donor bone marrow and is infused into patients with an average age of 76 years old. The good news is that patients in both the phase 1 and phase 2 clinical trials have shown no adverse effects to treatment.

This is excellent news and now paves the way to move to phase 3 clinical trials, which are larger-scale tests to further determine the efficacy and compare it to the best currently available treatments, for which there are basically none beyond simple coping approaches, such as walking sticks and frames to compensate for frailty.

It is also important to note that at this at this point, the drug or therapy is accepted as having some effect. You can read more about the clinical trial process and what each phase means here.

In the first trial, 15 patients with age-related frailty were given a single transplant of MSCs from donors aged between 20 and 45.Ā [6] Six months later, all patients in the trial showed an improved level of fitness, lower levels of inflammatory tumor necrosis factor (TNF), and improved quality of life in general. TNF is one of the regulators of inflammation and contributes to the chronic age-related inflammation known as ā€œinflammagingā€, which drives a number of age-related diseases.Ā [7]

The second trial was a randomized, double-blind study including a placebo group. An improved physical performance level was observed in patients, and, again, the level of systemic TNF, and thus inflammation, was reduced.Ā [8] Once again, there were no adverse effects observed in the patients, and the researchers wrote:

Treated groups had remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome.

David G. Le Couter and colleagues have written about the clinical trials in a guest editorial in The Journals of Gerontology:

There are always caveats associated with interpreting efficacy in small numbers of subjects, yet it is remarkable that a single treatment seems to have generated improvement in key features of frailty that are sustained for many months.

The next step for the researchers here is to begin a phase 2b clinical trial with 120 patients in ten different locations. Following the conclusion of this, a large randomized phase 3 trial will be launched, and this will be the final barrier to public approval for the therapy.

Conclusion

With an ever-increasing number of aged people in our population, stem cells hold great potential for treating a number of age-related diseases and combating the disability and frailty that accompany the aging process. Developing therapies like these could potentially help older people to enjoy an improved level of physical performance and a better quality of life. Being able to remain mobile and independent as we grow older would be of huge benefit to not only the individual but also to families and society as a whole.

There are currently no FDA-approved treatments for age-related frailty, so this represents a huge unmet need that will only worsen with an increasingly aging population if those needs are not met by new medicines.

Seeing such tangible results in humans is a clear indication of the potential of rejuvenation biotechnology, and how we regard and treat aging will be changing in the near future.

Literature

[1] Nardi, N. B., & da Silva Meirelles, L. (2008). Mesenchymal stem cells: isolation, in vitro expansion and characterization. In Stem cells (pp. 249-282). Springer Berlin Heidelberg.

[2] Stolzing, A., Jones, E., McGonagle, D., & Scutt, A. (2008). Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mechanisms of ageing and development, 129(3), 163-173.

[3] Wang, S., Qu, X., & Zhao, R. C. (2012). Clinical applications of mesenchymal stem cells. Journal of hematology & oncology, 5(1), 19.

[4] Danielyan, L., Beer-Hammer, S., Stolzing, A., SchƤfer, R., Siegel, G., Fabian, C., … & Novakovic, A. (2014). Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell transplantation, 23(1), S123-S139.

[5] Naaldijk, Y., Jaeger, C., Fabian, C., Leovsky, C., Blüher, A., Rudolph, L., … & Stolzing, A. (2017). Effect of systemic transplantation of bone marrow‐derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. Neuropathology and applied neurobiology, 43(4), 299-314.

[6]Ā Golpanian, S., DiFede, D. L., Khan, A., Schulman, I. H., Landin, A. M., Tompkins, B. A., … & Levis-Dusseau, S. (2017). Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, glx056.

[7] Franceschi, C., Garagnani, P., Vitale, G., Capri, M., & Salvioli, S. (2017). Inflammaging and ā€˜Garb-aging’. Trends in Endocrinology & Metabolism, 28(3), 199-212.

[8]Ā Tompkins, B. A., DiFede, D. L., Khan, A., Landin, A. M., Schulman, I. H., Pujol, M. V., … & Mushtaq, M. (2017). Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 72(11), 1513-1522.

 

About Steve Hill

As a scientific writer and a devoted advocate of healthy longevity technologies, Steve has provided the community with multiple educational articles, interviews, and podcasts, helping the general public to better understand aging and the means to modify its dynamics. His materials can be found at H+ Magazine, Longevity Reporter, Psychology Today, and Singularity Weblog. He is a co-author of the book Aging Prevention for All – a guide for the general public exploring evidence-based means to extend healthy life (in press).

About LIFE EXTENSION ADVOCACY FOUNDATION (LEAF)

In 2014, theĀ Life Extension Advocacy FoundationĀ was established as a 501(c)(3) non-profit organization dedicated to promoting increased healthy human lifespan through fiscally sponsoring longevity research projects and raising awareness regarding the societal benefits of life extension. In 2015 they launchedĀ Lifespan.io, the first nonprofit crowdfunding platform focused on the biomedical research of aging.

They believe that this will enable the general public to influence the pace of research directly. To date they have successfully supported four research projects aimed at investigating different processes of aging and developing therapies to treat age-related diseases.

The LEAF team organizesĀ educational events, takes part in different public and scientific conferences, and actively engages with the public on social media in order to help disseminate this crucial information. They initiate public dialogue aimed at regulatory improvement in the fields related to rejuvenation biotechnology.


Guest Articles
age-related frailty, aging, clinical trials, David G. Le Couter, FDA, FDA-approved, frailty, human clinical trials, human trials, LEAF, life extension, Life Extension Advocacy Foundation, longevity, Mesenchymal stem cells, MSCs, research, Stem Cell, Steve Hill

Post navigation

PREVIOUS
Sophia, The First Humanoid Robot Citizen – Article by Martin van der Kroon
NEXT
Test-Tube Tomato Still-Life – Painting by Ekaterinya Vladinakova

One thought on “Stem-Cell Clinical Trials Show Remarkable Results Against Age-Related Frailty – Article by Steve Hill”

  1. Pingback: Sunday 10th December | weekly global research

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Social Media

Constitution of the U.S. Transhumanist Party

Transhumanist Bill of Rights – Version 3.0

U.S. Transhumanist Party Facebook Feed

Free Transhumanist Symbols

Guidelines for Community Conduct

SUBMIT A POST

Subject Categories

    - Life Extension
    - Artificial Intelligence
    - Space Colonization
    - Robotics
    - Biotechnology
    - Nanotechnology
    - Autonomous Vehicles
    - 3D Printing
    - Cryptocurrencies
    - Vertical Farming
    - Universal Basic Income
    - Existential Risk
    - Rationality

Hashtags

    #USTranshumanistParty, #TranshumanistParty, #TranshumanistPolitics, #TomRoss2024, #RossTwedt2024

Recent Posts

  • MIND THE GAP: Bridging the Generation Gap in Longevity Science – Article by Tom Ross
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Michael Rae – August 6, 2023
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Adam Gries – August 13, 2023
  • U.S. Transhumanist Party Report from Longevity Summit Dublin 2023 – August 20, 2023
  • The U.S. Transhumanist Party Urges You to Sign the Dublin Longevity Declaration
  • U.S. Transhumanist Party Virtual Enlightenment Salon – USTP Officers’ Perspectives on Longevity
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Eleanor Davies – September 3, 2023
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Anastasia Egorova – September 10, 2023
  • U.S. Transhumanist Party Virtual Enlightenment Salon with David Patterson – September 17, 2023
  • U.S. Transhumanist Party Enlightenment Salon with Zack Varkaris / Austin Biotec – September 24, 2023
  • U.S. Transhumanist Party International Longevity Day Virtual Enlightenment Salon – October 1, 2023
  • Art Ramon Appointed as Chairman of Arizona Transhumanist Party as David Shumaker Transitions to Emeritus Role
  • RADICAL LIFE SUBTRACTION: Navigating An Uncomfortable Discourse – Article by Tom Ross
  • THE WA.I.TER RULE: Unveiling True Character Through AI Interactions – Article by Tom Ross
  • “PLAYING GOD” ACCUSATION: Unraveling the Controversy Surrounding Transhumanism – Article by Tom Ross
  • CONSPIRACY CAMPAIGN: Leaning into the Unconventional – Article by Tom Ross
  • Ending Aging Forum 2023 – Announcement by SENS Research Foundation
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Miguel Conner – July 16, 2023
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Brent Nally – July 2, 2023
  • U.S. Transhumanist Party Stream – Nigerian Student Tech Innovators: Nonso Nolly and Frederick Onwuka

Recent Comments

  • Dan Elton on Five Misconceptions About Radical Life Extension – Article by Arjun Khemani
  • CCRN on Five Misconceptions About Radical Life Extension – Article by Arjun Khemani
  • Vladimir Shakirov on U.S. Transhumanist Party General Discussion Thread for 2023
  • Zach Richardson on Five Misconceptions About Radical Life Extension – Article by Arjun Khemani
  • Jason Mallory on U.S. Transhumanist Party 2023 Electronic Primary Results – Tom Ross Endorsed as Candidate for President of the United States, Daniel Twedt Selected as Candidate for Vice-President

Archives

  • October 2023 (11)
  • September 2023 (6)
  • August 2023 (1)
  • July 2023 (4)
  • May 2023 (3)
  • April 2023 (3)
  • March 2023 (2)
  • February 2023 (12)
  • January 2023 (24)
  • December 2022 (2)
  • November 2022 (2)
  • October 2022 (3)
  • August 2022 (3)
  • July 2022 (2)
  • May 2022 (6)
  • March 2022 (3)
  • February 2022 (4)
  • January 2022 (7)
  • December 2021 (11)
  • November 2021 (4)
  • October 2021 (5)
  • September 2021 (2)
  • August 2021 (2)
  • July 2021 (4)
  • June 2021 (2)
  • May 2021 (6)
  • April 2021 (7)
  • March 2021 (4)
  • February 2021 (5)
  • January 2021 (6)
  • December 2020 (10)
  • November 2020 (4)
  • October 2020 (2)
  • September 2020 (1)
  • August 2020 (4)
  • July 2020 (5)
  • June 2020 (6)
  • May 2020 (3)
  • April 2020 (3)
  • March 2020 (6)
  • February 2020 (1)
  • January 2020 (6)
  • December 2019 (3)
  • November 2019 (2)
  • October 2019 (9)
  • September 2019 (10)
  • August 2019 (12)
  • July 2019 (18)
  • June 2019 (17)
  • May 2019 (12)
  • April 2019 (8)
  • March 2019 (12)
  • February 2019 (7)
  • January 2019 (13)
  • December 2018 (9)
  • November 2018 (5)
  • October 2018 (9)
  • September 2018 (5)
  • August 2018 (10)
  • July 2018 (13)
  • June 2018 (14)
  • May 2018 (8)
  • April 2018 (8)
  • March 2018 (10)
  • February 2018 (15)
  • January 2018 (17)
  • December 2017 (8)
  • November 2017 (17)
  • October 2017 (19)
  • September 2017 (11)
  • August 2017 (11)
  • July 2017 (16)
  • June 2017 (15)
  • May 2017 (10)
  • April 2017 (7)
  • March 2017 (8)
  • February 2017 (16)
  • January 2017 (8)
  • December 2016 (6)
  • November 2016 (5)

Categories

  • Allied Projects
  • Announcements
  • Art
  • Candidates
  • Discussion Panels
  • Distributed Computing
  • Exposure Periods
  • Foreign Ambassadors
  • General Discussion
  • Guest Articles
  • Inclusion
  • Interviews
  • Official Ballots
  • Petitions
  • Platform
  • Presentations
  • Press Releases
  • Research
  • Sample Ballots
  • Science Fiction
  • Statements
  • Tolerance
  • Virtual Enlightenment Salons
  • Vote Results
  • Working Groups

Victor Run Virtual Race – June 4-6, 2021

Historical Archive – 2020 U.S. Presidential Ticket – Charlie Kam and Liz Parrish

© 2023   Copyright - U.S. Transhumanist Party - All Rights Reserved | WordPress design: Art Ramon Paintings